Targovax (TRVX) Småprat

[sparkonge]

Ingenting er umulig med høy nok utvanning:)

[ufo]

Triste greier (så langt)
Dette fortjente ikke Targovax.

Selskapet blir utsatt for dobbel negativ fokus.
De gikk jo helt fra TG-platformen for en tid siden pga konkurransen.

Så skjer pigade meg det samme igjen , hvordan er det mulig?

Normalt så skulle jo prisen vært betalt første gangen TG-platformen ble “forlatt”
Hadde en avsluttet dette og konsentrert seg om oncus den gangen konkurransesituasjonen oppstod (som ville vært det normale) så ville vi diskutert oncos og unngått dette meningsløse fallet.

Vi kan jo fortsette i samme tralten og selv jekke ned mcap til den er null.

Det er jo litt underlig at vi er så opptatt av TG når det er opplest og vedtatt at oncus er en mye hottere sak.

Hvor forsvinner alle pengene ??

[Cinvest]

Vi er avhengig av å levere gode data, men jeg fikk inntrykk av at de var fornøyde med ONCOS fremgangen i de respektive studiene. Det vi fikk vite om opplegget i samarbeidet med AZ var jo særdeles interessant, og blir spennende data i H2!

Mesotheliom som er ferdigrekruttert bekreftet de vell også vil komme med avlesning før en ny emisjon. Så det kan absolutt generes verdier her for den langsiktige. Den kortsiktige gleden mot ovennevnte derimot er heller snevert.

[Laffe]

Over 2 år med total utbombing av denne aksjen nå. Toppen var i Mars 2017, til all time low i dag.

Interessant å merke seg dette da det er så påfallende. En del av de andre norske biotek-selskapenes kurser oppfører seg ikke slik.

[Buffet]

Sant nok. Veldig lav kurs og at de for låne aksjer av healthcap slik at de kan selge seg ut med en gang de har betalt så går det nok.

[Whatsthat]

bekreftet de vell også vil komme med avlesning før en ny emisjon.

Gjorde de det???

[anon79663630]

Bekreftet vel ikke akkurat, men det ble nevnt forventninger om det ja.

[Whatsthat]

Mesothelioma kommer jo ikke før nytt år… de henter aldri penger under 100mnok kontantbeholdning. Burn rate må såfall minkes kraftig…

[Martins]

Gratulerer til de som fikk kjøpt på dagens nivåer. Dere fikk mye bedre inngang enn meg ihvertfall Dagens sluttkurs 5,67kr. Forventningen var 9kr+ i dag på gode TG-resultater fra min side. Så feil kan man ta. Får lære av det

[Cinvest]

Gjorde de det???

Bekreftet var vell kanskje litt å ta i, men jeg forstod de indikerte det.

[Buffet]

Kursen halverer seg jo nesten en gang i halvåret her…

[Whatsthat]

Må sjekke denne i opptak da. Basert på det som er kommunisert i forhold til pengebeholdning, emi vinduer og tidspunkter virker nyttår å være over grensen. burn rate blir avgjørende da om de ikke finner alternativer til inntekt. Ref AZ - Transgene…

[anon79663630]

Burn rate kan ikke forventes å bli vesentlig mindre på kort sikt. Det ble bekreftet.

[optimist1]

Lurer på hva Targovax skal på Asco å gjøre?

[Klomp]

Oncos

[Cinvest]

Regner med de skal nettverke og sikkert satt opp noen 1:1 møter med fagpersoner eller selskaper. De skal vell ikke utifra det jeg vet presentere noe data der.

[Cinvest]

I studien med CRI/AZ.

Jaderberg snakket om oppsettet, og hva som må til for å utøke kohortene

colorectal 13 pasienter Ser man klinisk respons i minimum 1 av de 13 --> vil man øke kohorten
Overian : 18 pasienter. Svarer de første 5 pasientene klinisk --> da er det et signal for hele studiegruppen og man utøker kohorten.

Jeg fikk kun høre i farten, men sa de at de var ferdig rekruttert? Kunne virke som det ihverfall var veldig nære etter god rekruttering i våres,
Ca 19:00 og ut i videoen.

[TekBot]

23/05-2019 17:11:51: (TRVX) TARGOVAX ASA - APPROVAL AND PUBLICATION OF SUPPLEMENTAL PROSPECTUS

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED
STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE
PEOPLE’S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE
…

Vis børsmeldingen

DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.
PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE PRESS RELEASE.

Oslo, 23 May 2019: Reference is made to the stock exchange announcement by
Targovax ASA (OSE:TRVX) (“Targovax” or the “Company”) on 8 May 2019, regarding
the completion of the enrollment of the ONCOS-102 trial in pleural mesothelioma
and the announcements on 23 May 2019 regarding median and three-year overall
survival for TG01 trial in resected pancreatic cancer and the decision to focus
fully on the Company’s ONCOS oncolytic virus program going forward.

The Financial Supervisory Authority of Norway (Nw.: Finanstilsynet) has today
approved a supplemental prospectus dated 23 May 2019 (the “Supplemental
Prospectus”) to the Company’s prospectus dated 27 March 2019, as amended by a
supplemental prospectus dated 12 April 2019 (the “Prospectus”). The information
contained in the Supplemental Prospectus shall be considered an integral part
of, and is to be read together with, the Prospectus.

Subscribers that have subscribed for offer shares before the publication of the
Supplemental Prospectus have the right to withdraw their subscription within two
days after the publication of the Supplemental Prospectus, cf. Section 7-21(2)
of the Norwegian Securities Trading Act (i.e. prior to 16:30 hours (CEST) on 27
May 2019) (including for subscriptions made through the VPS online subscription
system). Such withdrawal is made by contacting the Manager.

The Prospectus and the Supplemental Prospectus are available on the following
websites: www.targovax.com and www.dnb.no/emisjoner. Hard copies of the
Prospectus and the Supplemental Prospectus may also be obtained at the offices
of Targovax ASA, Lilleakerveien 2 C, 0283 Oslo, Norway or by contacting DNB
Markets at +47 23 26 81 01.

For further information, please contact:

Torbjørn Furuseth, CFO
Phone: +47 932 11 101
Email: torbjorn.furuseth@targovax.com

About Targovax

Activating the patient’s immune system to fight cancer

Targovax (OSE:TRVX) is a clinical stage biotechnology company developing immune
activators to target hard-to-treat solid tumors. Immuno-oncology is currently
one of the fastest growing therapeutic fields in medicine.

Targovax’s lead product candidate, ONCOS-102, is a genetically modified
oncolytic adenovirus, which has been engineered to selectively infect and
replicate in cancer cells. It has been shown to activate the immune system to
generate tumor-specific immune responses. In phase I trials, ONCOS-102 induced
both local and systemic innate and adaptive immune activation, which has been
associated with clinical benefit. ONCOS-102’s targeted path-to-market indication
is mesothelioma, where the virus is currently being tested in a randomized phase
II trial. Another trial, in checkpoint inhibitor refractory advanced melanoma,
is expected to produce important proof-of-concept immune activation data in
heavily pre-treated patients.

IMPORTANT INFORMATION

These materials do not constitute an offer of securities for sale or a
solicitation of an offer to purchase securities of the Company in the United
States or any other jurisdiction. The securities of the Company may not be
offered or sold in the United States absent registration or an exemption from
registration under the U.S. Securities Act of 1933, as amended (the “U.S.
Securities Act”). The securities of the Company have not been, and will not be,
registered under the U.S. Securities Act. Any sale in the United States of the
securities mentioned in this communication will be made solely to “qualified
institutional buyers” as defined in Rule 144A under the U.S. Securities Act. No
public offering of the securities will be made in the United States.

In any EEA Member State, this communication is only addressed to and is only
directed at qualified investors in that Member State within the meaning of the
Prospectus Directive, i.e., only to investors who can receive the offer without
an approved prospectus in such EEA Member State. The expression “Prospectus
Directive” means Directive 2003/71/EC as amended (together with any applicable
implementing measures in any Member State.

In the United Kingdom, this communication is only addressed to and is only
directed at Qualified Investors who (i) are investment professionals falling
within Article 19(5) of the Financial Services and Markets Act 2000 (Financial
Promotion) Order 2005 (as amended) (the “Order”) or (ii) are persons falling
within Article 49(2)(a) to (d) of the Order (high net worth companies,
unincorporated associations, etc.) (all such persons together being referred to
as “Relevant Persons”). These materials are directed only at Relevant Persons
and must not be acted on or relied on by persons who are not Relevant Persons.

Any investment or investment activity to which this announcement relates is
available only to Relevant Persons and will be engaged in only with Relevant
Persons. Persons distributing this communication must satisfy themselves that it
is lawful to do so.

Matters discussed in this announcement may constitute forward-looking
statements. Forward-looking statements are statements that are not historical
facts and may be identified by words such as “anticipate”, “believe”,
“continue”, “estimate”, “expect”, “intends”, “may”, “should”, “will” and similar
expressions. The forward-looking statements in this release are based upon
various assumptions, many of which are based, in turn, upon further assumptions.

Although the Company believes that these assumptions were reasonable when made,
these assumptions are inherently subject to significant known and unknown risks,
uncertainties, contingencies and other important factors which are difficult or
impossible to predict and are beyond its control. Such risks, uncertainties,
contingencies and other important factors could cause actual events to differ
materially from the expectations expressed or implied in this release by such
forward-looking statements. The information, opinions and forward-looking
statements contained in this announcement speak only as at its date, and are
subject to change without notice.

This announcement is made by and, and is the responsibility of, the Company. The
Manager is acting exclusively for the Company and no one else and will not be
responsible to anyone other than the Company for providing the protections
afforded to their respective clients, or for advice in relation to the contents
of this announcement or any of the matters referred to herein.

Neither the Manager nor any of its respective affiliates makes any
representation as to the accuracy or completeness of this announcement and none
of them accepts any responsibility for the contents of this announcement or any
matters referred to herein.

This announcement is for information purposes only and is not to be relied upon
in substitution for the exercise of independent judgment. It is not intended as
investment advice and under no circumstances is it to be used or considered as
an offer to sell, or a solicitation of an offer to buy any securities or a
recommendation to buy or sell any securities of the Company. Neither the Manager
nor any of its affiliates accepts any liability arising from the use of this
announcement.

Each of the Company, the Manager and their respective affiliates expressly
disclaims any obligation or undertaking to update, review or revise any
statement contained in this announcement whether as a result of new information,
future developments or otherwise.

The distribution of this announcement and other information may be restricted by
law in certain jurisdictions. Persons into whose possession this announcement or
such other information should come are required to inform themselves about and
to observe any such restrictions.

This information is subject to disclosure requirements pursuant to Section 5-12
of the Norwegian Securities Trading Act.

http://www.netfonds.no/quotes/release.php?id=20190523.OBI.20190523S133

[hansi]

Forstår jeg riktig her? Vi som har tegnet oss allerede får mulighet til å trekke oss?

[Chrysler300C]

Ja, innen mandag 27. Kl 16.30

Subscribers that have subscribed for offer shares before the publication of the
Supplemental Prospectus have the right to withdraw their subscription within two
days after the publication of the Supplemental Prospectus, cf. Section 7-21(2)
of the Norwegian Securities Trading Act (i.e. prior to 16:30 hours (CEST) on 27
May 2019) (including for subscriptions made through the VPS online subscription
system). Such withdrawal is made by contacting the Manager